We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IBM Watson Partners with Illumina to Advance Cancer Research
Read MoreHide Full Article
International Business Machines Corporation (IBM - Free Report) -owned IBM Watson Health and San Diego-based genome sequencing firm Illumina (ILMN - Free Report) have inked a partnership to achieve better interpretation of genome data through the integration of Watson for Genomics with Illumina’s tumor sequencing protocol and the BaseSpace Sequence Hub.
Cancer researchers who currently use Illumina’s TruSight Tumor 170 (a cancer genome sequencing panel) will be benefitted due to this partnership as the integration with Watson for Genomics will pave the way for rapid access and interpretation of a wide array of genome data that is currently being produced by the TrueSight Tumor 170.
The integration is expected to be complete by early 2017.
International Business Machines Corporation Price and Consensus
Also, during the same time, IBM’s Watson was adopted by Unruly, a British ad tech company to build a new cognitive powered psychographic targeting tool in order to make digital video ads more audience targeted and thus, more effective. (Read More: IBM Watson to Make Unruly's Digital Video Ads More Targeted)
Per an IDC report, worldwide spending on cognitive systems and artificial intelligence is estimated to be over $47 billion by 2020 from $8 billion at present. The segment is projected to grow at a CAGR of 55.1%. However, with the presence of big players like Alphabet (GOOGL - Free Report) -owned Google’s DeepMind, Amazon’s (AMZN - Free Report) Amazon AI and Microsoft’s Artificial Intelligence and Research Group, stiff competition persists.
Given IBM Watson’s growing popularity, we anticipate to see more of such adoptions in the future, which will definitely have a positive impact on the company’s bottom line.
Stock Performance Overview
Shares of IBM have underperformed the broader Zacks Computer Integrated Systems industry over the last 12 months. While the industry generated a return of 38.4%, the stock gained 25.9%.
The underperformance of the stock could be attributed to the ongoing and heavily time-consuming business model transition to the cloud. Further, sluggish IT spending, particularly in the on-premises and data center hardware and foreign exchange volatility remain the primary concerns. Also, intensifying competition in the cloud is a major headwind.
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
IBM Watson Partners with Illumina to Advance Cancer Research
International Business Machines Corporation (IBM - Free Report) -owned IBM Watson Health and San Diego-based genome sequencing firm Illumina (ILMN - Free Report) have inked a partnership to achieve better interpretation of genome data through the integration of Watson for Genomics with Illumina’s tumor sequencing protocol and the BaseSpace Sequence Hub.
Cancer researchers who currently use Illumina’s TruSight Tumor 170 (a cancer genome sequencing panel) will be benefitted due to this partnership as the integration with Watson for Genomics will pave the way for rapid access and interpretation of a wide array of genome data that is currently being produced by the TrueSight Tumor 170.
The integration is expected to be complete by early 2017.
International Business Machines Corporation Price and Consensus
International Business Machines Corporation Price and Consensus | International Business Machines Corporation Quote
What Does this Mean for IBM?
Notably, this is yet another win for IBM’s Watson which is increasingly seeing adoptions across various industries.
During Dec 2016, IBM’s Watson was adopted by the Lotte Group to drive innovation across its business verticals. (Read More: IBM's Watson to Enable Lotte Gain Insight into Customer Data).
Also, during the same time, IBM’s Watson was adopted by Unruly, a British ad tech company to build a new cognitive powered psychographic targeting tool in order to make digital video ads more audience targeted and thus, more effective. (Read More: IBM Watson to Make Unruly's Digital Video Ads More Targeted)
Per an IDC report, worldwide spending on cognitive systems and artificial intelligence is estimated to be over $47 billion by 2020 from $8 billion at present. The segment is projected to grow at a CAGR of 55.1%. However, with the presence of big players like Alphabet (GOOGL - Free Report) -owned Google’s DeepMind, Amazon’s (AMZN - Free Report) Amazon AI and Microsoft’s Artificial Intelligence and Research Group, stiff competition persists.
Given IBM Watson’s growing popularity, we anticipate to see more of such adoptions in the future, which will definitely have a positive impact on the company’s bottom line.
Stock Performance Overview
Shares of IBM have underperformed the broader Zacks Computer Integrated Systems industry over the last 12 months. While the industry generated a return of 38.4%, the stock gained 25.9%.
The underperformance of the stock could be attributed to the ongoing and heavily time-consuming business model transition to the cloud. Further, sluggish IT spending, particularly in the on-premises and data center hardware and foreign exchange volatility remain the primary concerns. Also, intensifying competition in the cloud is a major headwind.
Zacks Rank
At present, IBM carries a Zacks Rank #4 (Sell). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Zacks' Top 10 Stocks for 2017
In addition to the stocks discussed above, would you like to know about our 10 finest tickers for the entirety of 2017?
Who wouldn't? These 10 are painstakingly hand-picked from 4,400 companies covered by the Zacks Rank. They are our primary picks to buy and hold. Be among the very first to see them >>